Accelerate Diagnostics, Inc. (BMV:AXDX)

Market Cap	463.36
Revenue (ttm)	243.76M
Net Income (ttm)	-1.04B
Shares Out	n/a
EPS (ttm)	-44.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,612
Average Volume	839
Open	2.690
Previous Close	14.310
Day's Range	1.700 - 2.690
52-Week Range	1.700 - 25.000
Beta	n/a
RSI	23.13
Earnings Date	Sep 18, 2025

About Berry Global Group

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides Accelerate PhenoTest BC Kit, a test kit for the system, which is indicated as an aid, in conjuncti...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1982
• Employees: 107
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: AXDX

Financial Performance

In 2024, Accelerate Diagnostics's revenue was $11.70 million, a decrease of -2.99% compared to the previous year's $12.06 million. Losses were -$50.05 million, -18.78% less than in 2023.